DK0592636T3 - Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi - Google Patents

Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi

Info

Publication number
DK0592636T3
DK0592636T3 DK93908990T DK93908990T DK0592636T3 DK 0592636 T3 DK0592636 T3 DK 0592636T3 DK 93908990 T DK93908990 T DK 93908990T DK 93908990 T DK93908990 T DK 93908990T DK 0592636 T3 DK0592636 T3 DK 0592636T3
Authority
DK
Denmark
Prior art keywords
infected
culture
preparing
cell culture
cultivation
Prior art date
Application number
DK93908990T
Other languages
English (en)
Inventor
Herve Perron
Jean-Marie Seigneurin
Original Assignee
Bio Merieux
Univ Grenoble 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9204322A external-priority patent/FR2689519B1/fr
Application filed by Bio Merieux, Univ Grenoble 1 filed Critical Bio Merieux
Application granted granted Critical
Publication of DK0592636T3 publication Critical patent/DK0592636T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK93908990T 1992-04-03 1993-04-02 Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi DK0592636T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9204322A FR2689519B1 (fr) 1992-04-03 1992-04-03 Procédé de culture in vitro de cellules infectées par un virus associé à la sclérose en plaques et lignées cellulaires obtenues.
FR9213447A FR2689521B1 (fr) 1992-04-03 1992-11-03 Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
PCT/FR1993/000337 WO1993020189A1 (fr) 1992-04-03 1993-04-02 Procede d'obtention d'une culture cellulaire viable infectee par un virus associe a la sclerose en plaques

Publications (1)

Publication Number Publication Date
DK0592636T3 true DK0592636T3 (da) 1999-08-09

Family

ID=26229389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93908990T DK0592636T3 (da) 1992-04-03 1993-04-02 Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi

Country Status (8)

Country Link
US (2) US5585262A (da)
EP (1) EP0592636B1 (da)
AT (1) ATE173760T1 (da)
CA (1) CA2110702C (da)
DE (1) DE69322227T2 (da)
DK (1) DK0592636T3 (da)
FR (1) FR2689521B1 (da)
WO (1) WO1993020189A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689520B1 (fr) 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
DE69533863T2 (de) * 1994-02-04 2006-02-16 Bio Merieux MSRV1 Virus der mit Multipler Sklerose verbunden ist, seine nukleären Bestandteile und Verwendungen
FR2716198B1 (fr) * 1994-02-15 1996-04-19 Bio Merieux Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification.
FR2737500B1 (fr) 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
JP4226657B2 (ja) 1996-11-26 2009-02-18 ベーイーオー メリュー 診断、予防、及び治療のための、多発性硬化症に関連するウイルス性物質及びヌクレオチド断片
FR2765588A1 (fr) 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133829A (en) * 1978-08-24 1982-10-19 Neil J.L. Gilmour Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) * 1988-01-29 1989-08-02 City Of Hope Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
WO1993023550A2 (en) * 1992-05-18 1993-11-25 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus

Also Published As

Publication number Publication date
EP0592636A1 (fr) 1994-04-20
CA2110702A1 (fr) 1993-10-14
ATE173760T1 (de) 1998-12-15
WO1993020189A1 (fr) 1993-10-14
CA2110702C (fr) 2004-06-22
FR2689521A1 (fr) 1993-10-08
FR2689521B1 (fr) 1996-07-19
US5925555A (en) 1999-07-20
DE69322227D1 (de) 1999-01-07
DE69322227T2 (de) 1999-04-22
US5585262A (en) 1996-12-17
EP0592636B1 (fr) 1998-11-25

Similar Documents

Publication Publication Date Title
DE3853422D1 (de) HIV-3-Retrovirus und seine Verwendung.
Steinitz et al. Comparison between growth characteristics of an Epstein--Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro.
DK0414475T3 (da) Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
DK0587873T3 (da) Fremgangsmåde til opnåelse af celler, der er inficeret med en virus, der er forbundet med dissemineret sklerose
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
AU588885B2 (en) Production of viral antigens
DK0592636T3 (da) Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi
EP0019218A3 (en) Influenza virus vaccines, process for preparing them, process for propagating influenza viruses and cell culture inoculated with influenza virus
ES8200227A1 (es) Procedimiento de obtencion de vacunas de bronquitis in- fecciosa para aves de corral
ES8105930A1 (es) Procedimiento para la preparacion de vacunas de virus poli- valentes
KR900702045A (ko) 천연 hiv gp 160의 제조방법
ES432385A1 (es) Un metodo de obtener una cepa de virus de la gripe.
GB1358321A (en) Method od tissue cell culture
Steinitz et al. Inhibition of DNA metabolism in human B lymphocytes by a substrain of Epstein-Barr virus (P3HR-1): a method for virus quantitation
Majer et al. Results of chromosome analysis of rabies virus infected human diploid cells (WI-38)
Timanovskaia et al. Malignant lymphoma in rabbits induced by the administration of herpes virus-containing material from brown macaques
JPS6485092A (en) Production of protein
AWA et al. A Preliminary Note on the Chromosomes of the McCoy Synovial Cell Line Cultivated in vitro (With 7 Text-figures and 2 Tables)
Husson-van Vliet Comparison of two cellular supports for control of the temperature marker of attenuated poliovirus strains.
SU1540269A1 (ru) Штамм гибридных культивируемых клеток животного mus musculus, используемый для получения моноклональных антител к поверхностному гликопротеину вирусов комплекса клещевого энцефалита